相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment
Akihiro Tobe et al.
CLINICAL DRUG INVESTIGATION (2020)
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial
Tze-Fan Chao et al.
EUROPEAN HEART JOURNAL (2019)
Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function
Sophie Testa et al.
THROMBOSIS RESEARCH (2019)
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation A Nationwide Cohort Study
Hee Tae Yu et al.
STROKE (2018)
Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban
Teruhiro Sakaguchi et al.
JOURNAL OF CARDIOLOGY (2017)
Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
Alexander G. G. Turpie et al.
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE (2017)
Edoxaban in patients with atrial fibrillation
Mon Eisen et al.
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE (2017)
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
Erin A. Bohula et al.
CIRCULATION (2016)
Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation
Hiroyuki Osanai et al.
CIRCULATION JOURNAL (2016)
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Kevin E. Chan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants
Janice B. Schwartz
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2016)
Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation
Hiroyuki Osanai et al.
CIRCULATION JOURNAL (2015)
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Edoxaban: a focused review of its clinical pharmacology
Gregory Y. H. Lip et al.
EUROPEAN HEART JOURNAL (2014)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
Jeffrey I. Weitz et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
